FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive pain medicine.

The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the Sackler family too much protection.

After its January FDA approval for moderate to severe acute pain in adults, the company priced Journavx at $15.50 per 50mg tablet.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here to read why PCRX stock is a Buy.

Sold as Journavx, the drug received U.S. approval in late January as a treatment for the short-lived “acute” pain typically felt after an operation or accident. Journavx works differently than ...

The medication, called Journavx, was approved in the United States in January. The financial success of new drugs largely depends on how they’re treated by pharmacy benefit managers that ...

Journavx costs $15.50 per 50 mg tablet, taken twice daily, making it pricier than opioids. Vertex's Q4 sales hit $2.91 billion, up 16% YoY, beating the $2.78 billion consensus. Learn how to trade ...

The FDA’s landmark approval of Journavx (suzetrigine)—the first non-opioid pain reliever in over two decades—represents a breakthrough in pain management. This breakthrough underscores the urgent need ...